[1] Liu Z, Suo C, Mao X, et al. Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990-2017. Cancer, 2020, 126(10):2267-2278. [2] 马宏宇, 敖杨坤, 刘文斌,等. 中国肝癌相关队列研究的文献计量分析. 中华流行病学杂志, 2020, 41(1):115-119. [3] Valery PC, Laversanne M, Clark PJ, et al. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology, 2018, 67(2):600-611. [4] Chen J, Zhang Y, Cai H, et al. Comparison of the effects of postoperative prophylactic transcatheter arterial chemoembolization (TACE) and transhepatic arterial infusion (TAI) after hepatectomy for primary liver cancer. J BUON, 2018, 23(3):629-634. [5] Hayashi M, Kawana S, Sekino H, et al. Contrast uptake in primary hepatic angiosarcoma on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the hepatobiliary phase. World J Hepatol, 2018, 10(1):166-171. [6] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1)S9-32. [7] 周新凤, 魏志梅, 周成宇, 等. 顺德地区不同性别人群的肝癌影响因素分析. 中华疾病控制杂志, 2019, 23(2):129-133. [8] Allaire M, Nahon P, Layese R, et al. Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication. Hepatology, 2018, 68(4):1245-1259. [9] 朱凯, 许乙凯. 肝脏特异性对比剂钆塞酸二钠预测肝癌微血管浸润的研究进展. 中华放射学杂志, 2019, 53(12):1037-1039. [10] Inchingolo R, Faletti R, Grazioli L, et al. MR with Gd-EOB-DTPA in assessment of liver nodules in cirrhotic patients. World J Hepatol, 2018, 10(7):462-473. [11] Verloh F. Diagnostic performance of Gd-EOB-DTPA-enhanced MRI for evaluation of liver dysfunction: a multivariable analysis of 3T MRI sequences. Oncotarget, 2018, 9(91):36371-36378. [12] Renzulli M, Biselli M, Brocchi S, et al. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut, 2018, 67(9):1674-1682. [13] 胡梦洁, 郁义星, 范艳芬, 等. 钆塞酸二钠增强磁共振影像学特征联合定量分析在预测肝细胞癌病理分级中的价值. 中华医学杂志, 2020, 100(17):1299-1304. [14] Li XQ, Wang X, Zhao DW, et al. Application of Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma. World J Surg Oncol, 2020, 18(1):219-222. [15] Feng ST, Jia Y, Liao B, et al. Preoperative prediction of microvascular invasion in hepatocellular cancer: a radiomics model using Gd-EOB-DTPA-enhanced MRI. Eur Radiol, 2019, 29(9):4648-4659. [16] Chen S, Feng S, Wei J, et al. Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging. Eur Radiol, 2019, 29(8):4177-4187. [17] Lee Y, Kim SY, Lee SS, et al. Pitfalls in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging with an emphasis on nontumorous lesions. Clin Liver Dis (Hoboken), 2018, 12(2):50-59. [18] Tang Q, Ma C. Performance of Gd-EOB-DTPA-enhanced MRI for the diagnosis of LI-RADS 4 category hepatocellular carcinoma nodules with different diameters. Oncol Lett, 2018, 16(2):2725-2731. [19] Galia M, Agnello F, Sparacia G, et al. Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients. Radiol Med, 2018, 123(7):489-497. [20] Son J, Hwang SH, Park S, et al. Imaging features of hepatocellular carcinoma: quantitative and qualitative comparison between MRI-enhanced with Gd-EOB-DTPA and Gd-DTPA. Invest Radiol, 2019, 54(8):494-499. |